Medical Pharmacology Chapter 30: Thyroid and Antithyroid Drugs
Definition: clinical, physiological, biochemical consequences when tissues respond to excess thyroid hormone
Most important causes: those associated with prolonged hormone overproduction by the thyroid.
Extra-pituitary unregulated thyroid stimulation:
Graves' disease
Hashimoto's disease
trophoblastic tumor
Chronic thyroiditis
Excessive TSH secretion by pituitary tumor (rare)
Autonomous thyroid gland hyperfunction
Ingestion of meat contaminated with animal thyroids ("hamburger toxicosis")
Hyperthyroidism is only associated with conditions in which thyroidal hyperfunction leads to thyrotoxicosis.
Hyperthyroidism with diffuse goiter
Dermopathy
Ophthalmopathy
Soft, enlarged, vascular
Parenchymal hypertrophy/hyperplasia
Lymphocytic infiltration (suggesting the immunological nature of the disease)
|
Graves' disease: other involvements
Generalized lymphoid hyperplasia and infiltration
Spleenic or thymic enlargement
Thyrotoxicosis associated with:
Skeletal muscle fiber degeneration
Cardiac enlargement
Diffuse liver fibrosis with fatty infiltration
Skeletal decalcification
Body tissue loss
Ophthalmopathy: characterized by:
Inflammatory orbital content infiltrate (lymphocytes, mast cells, plasma cells)
Enlargement of orbital musculature (lymphocytes infiltration, mucopolysaccharides, edema, fat)
Eventually muscle fiber degeneration; loss of striations; fibrosis
Dermal thickening (lymphocytes infiltration; mucopolysaccharides)
Clinical Presentations of Thyrotoxicosis
Common manifestations (thyrotoxicosis)
Nervousness, insomnia, tremors, frequent bowel movements, heat intolerance, sweating, emotional instability
Weight loss despite adequate or increased appetite
Muscle weakness
Oligomenorrhea/amenorrhea in premenstrual women
Dyspnea
Palpitations
Exacerbation of angina/cardiac failure (older patients)
Ocular Presentations: (distinct from ophthalmopathy associated with Graves' disease)
Ocular signs mainly due to excessive sympathetic stimulation
Characteristics stare (widening palprebral fissures)
Lid lag
Infrequent blinking
Failure to wrinkle brow upon upward gaze
Wide pulse pressure
Sinus tachycardia
Atrial arrhythmias (particularly atrial fibrillation)
Systolic murmurs
Occasionally heart failure
Clinical Presentations of Graves' disease
Common manifestations:
Hyperfunctioning goiter
Asymmetric, lobular
Ophthalmopathy
Two components: spastic and mechanical
Spastic-- stare, lid lag, lid retraction
Poptosis (sensitive to antiadrenergic agents) including:
Ophthalmoplegia
Periorbital swelling
Conjunctivitis
Corneal ulceration, optic neuritis, optic atrophy
Diagnosis:
In addition to physical manifestations described earlier:
Undetectable TSH
Usually increased values of T4 and T3.
Fulminating increase in symptoms of thyrotoxicosis
"Medical storm" is now likely to be seen in undertreated patients.
Precipitated by surgery or complicating illness, often sepsis.
Presenting syndrome:
Extreme irritability
Coma or delirium
High fever, 41oC
Tachycardia
Hypotension
Vomiting
Diarrhea
Treatment:
Manage dehydration: IV glucose/Saline, vitamin B complex
Glucocorticoids (possible reduction in adrenal reserve; increase glucocorticoid requirement and thyrotoxicosis
Digitalis may be required to control elevated ventricular rates in the presence of atrial fibrillation
Block hormone synthesis by large dose propylthiouracil; followed by large doses of iodine, oral or parenteral; sodium ipodate may be used instead of iodine
Propranolol (adrenergic antagonist) important in the absence of CHF
Combination treatment with propylthiouracil, iodine, dexamethasone is likely to result in serum T3 levels returning to normal within one to two days.
|
|
Greenspan, F.S., and Dong, B. J.. Histamine, Thyroid and Antithyroid Drugs, in Basic and Clinical Pharmacology, (Katzung, B. G., ed) Appleton-Lange, 1998, pp 619-633.
Wartofsky, L., Diseases of the Thyroid, In Harrison's Principles of Internal Medicine 14th edition, (Isselbacher, K.J., Braunwald, E., Wilson, J.D., Martin, J.B., Fauci, A.S. and Kasper, D.L., eds) McGraw-Hill, Inc (Health Professions Division), 1998, pp 2012-2034
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials, that are believed reliable and consistent with standards accepted at the time of development. Possibility of human error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete. Users should confirm the information contained herein with other sources. This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site. Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals. Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. Advertisements that appear on this site are not reviewed for content accuracy and it is the responsibility of users of this website to make individual assessments concerning this information. Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals. |